Cand.med Line Veronika Hjelle disputerer for ph.d.-graden i helsevitenskap og vil offentlig forsvare avhandlingen:
“Serum Platinum retention and long-term effects in Testicular cancer survivors”
Kort sammendrag av avhandlingen:
Testicular cancer, the most prevalent malignancy in young men, has a remarkable survival due to chemotherapy treatment with cisplatin. For some, cure comes with the expense of late effects due to treatment. Cisplatin eliminates slowly from the body, and small amounts of platinum, the metal compound of cisplatin, are retained in the body for years after treatment. In our study, testicular cancer survivors have higher platinum levels up to three decades after cisplatin treatment, compared with controls. Our results showed associations between the retained platinum and increased second cancer, tinnitus, and hypogonadism. A larger platinum decline was associated with worsened tinnitus and paresthesias, and a reduced risk of second cancers. The associations with the retained platinum and late effects may be due to the platinum’s ongoing damage to organs. (Avhandlingen er tilgjengelig for utlån hos Seksjon for forskningstjenester frem til disputasdato)
Veiledere
Hovedveileder førsteamanuensis Hege Sagstuen Haugnes
Biveileder Professor Roy Bremnes
Biveileder overlege Jan Olderburg
Bedømmelseskomiteen
Professor Jourik Gietema, University Medical Center Groningen, University of Groningen, Nederland – 1. opponent
Professor emeritus Olbjørn Harald Klepp, Institutt for Kreftforskning og molekylær medisin, Norges Teknisk-naturvitenskapelige universitet (NTNU), Trondheim – 2. opponent
Førsteamanuensis Marit Dahl Solbu, Institutt for Klinisk Medisin, Det helsevitenskapelige fakultet, UiT – Norges arktiske universitet – leder av komité
Disputasleder
Førsteamanuensis Marijke Van Ghelue, Institutt for klinisk medisin, Det helsevitenskapelige fakultet, Universitetet i Tromsø – Norges arktiske universitet
Prøveforelesning over oppgitt emne holdes kl. 10.15, samme sted: “Risk factors for late effects of chemotherapy treatment for patients with testicular cancer”